Skip to main content
Premium Trial:

Request an Annual Quote

Expression Pathology, Oridis to Offer Protein-Biomarker Services

NEW YORK (GenomeWeb News) — Expression Pathology has formed an alliance with the Austrian company Oridis Biomed to offer proteomic tissue-analysis services for protein biomarker research, the companies said today.
 
Under the agreement, both companies will be able to offer the collaborative research services to clients in the drug-development, medical-diagnostic, and academic spheres.
 
The collaboration will use Expression Pathology’s Liquid Tissue and Director mass spectrometry and proteomics technologies, along with Oridis’ Tissomics high-throughput platform, and its access to formalin-fixed tissue samples.
 
Expression Pathology CEO Casey Eitner said the alliance will help drug and diagnostic developers to identify and measure protein biomarkers that relate to specific disease progression, drug response, and toxicity.
 
Oridis CEO Peter Hecht said the collaboration will allow companies to use mass spec and other pathology techniques to “mine tissue archives with detailed clinical outcomes and pathology data."

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.